Metastatic castration-resistant prostate cancer (CRPC).
XTANDI™ (enzalutamide) is a leading treatment for men with metastatic castration-resistant prostate cancer (CRPC). Initially approved by the FDA in August 2012 and by the EMA in August 2013 for metastatic CRPC patients who were previously treated with chemotherapy, the approval was later expanded to all patients with metastatic CRPC regardless of whether they received prior chemotherapy.
Therapeutic Area
Oncology
Acquisition Date
Mar 2016
Marketer
Seller
